SMARCD1 is a dual regulator of PD-L1 expression and cell proliferation facilitating tumor evasion

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Cancer cells evade immune surveillance by overexpressing immune checkpoint regulators like PD-L1.
• Identifying novel targets that regulate PD-L1 expression is crucial for developing effective anti-tumor therapies.

Purpose of the Study:

• To identify novel regulators of PD-L1 expression in colorectal cancer (CRC).
• To investigate the role of SMARCD1, a SWI/SNF complex subunit, in promoting tumor immune evasion and proliferation.
• To explore SMARCD1 as a potential therapeutic target for CRC.

Main Methods:

• CRISPR-Cas9 screening to identify SMARCD1 as a PD-L1 regulator.
• Immunohistochemistry (IHC) to assess SMARCD1 expression in CRC tissues.
• In vitro assays (Western blotting, flow cytometry) to evaluate PD-L1 expression and tumor cell behavior (proliferation, invasion, migration, apoptosis).
• In vivo tumor models and molecular analyses (RNA-seq, ChIP-seq) to elucidate mechanisms.

Main Results:

• SMARCD1 is significantly upregulated in CRC tissues and promotes tumor growth by regulating PD-L1.
• SMARCD1 knockout reversed PD-L1 upregulation and tumor-promoting effects; SWI/SNF inhibitor FHT-1015 mimicked these effects.
• SMARCD1 appears to maintain chromatin accessibility at the PD-L1 regulatory element and activate the PI3K-Akt pathway.

Conclusions:

• SMARCD1 plays a critical role in regulating PD-L1 transcription and promoting colorectal cancer cell proliferation.
• SMARCD1 is a promising therapeutic target for colorectal cancer treatment due to its role in immune evasion and tumor growth.